Adjuvant Molecular Therapies in Breast Cancer
Targeted treatments act on particular cancer features and can reduce recurrence risk in selected patients.
The key things to know
- Tumour features and eligibility determine treatment.
- Targeted medicines still require regular monitoring.
Why the tumour profile matters
Breast cancers have different biological features. Pathology routinely checks hormone receptors and HER2, with other testing when relevant. These results help match treatment to a target. A new drug's availability does not mean it is appropriate for every person or every stage.
Examples of approaches
HER2-directed medicines may be used for HER2-positive disease. Selected higher-risk cases may qualify for a CDK4/6 inhibitor with endocrine therapy, or a PARP inhibitor when an eligible inherited alteration is present. Exact eligibility depends on diagnosis, previous treatment and locally applicable criteria.
Monitoring during treatment
Targeted does not mean free of side effects. Blood counts, liver tests or heart monitoring may be required, depending on the medicine. Digestive symptoms, fatigue and other problems can occur. Share all medicines and supplements, and promptly report significant new symptoms.
A shared decision
Ask about additional benefit, duration, administration and monitoring. Confirm access and coverage in Jordan before making travel or payment arrangements. Do not substitute or stop treatment independently: alternatives depend on the molecular target, disease stage and your overall health.
Take these questions to your appointment
- Which result makes me eligible for this treatment?
- What monitoring and financial arrangements are needed?
Sources & review
This is original educational content based on the sources below, not reproduced textbook material. Website supervisor: Dr. Nizar Ismail. Individual medical review of this article is pending.
This information cannot replace diagnosis or a personal treatment plan. Consult your care team about symptoms or decisions about your treatment.